TRANSLATIONAL RESEARCH: Edited by Jason Hsu and Sunir J. GargThe retina revolution: signaling pathway therapies, genetic therapies, mitochondrial therapies, artificial intelligenceWood, Edward H.a; Korot, Edwardb; Storey, Philip P.c; Muscat, Stephaniea; Williams, George A.d,e; Drenser, Kimberly A.d,eAuthor Information aDepartment of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California bMoorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK cAustin Retina Associates, Austin, Texas dWilliam Beaumont Hospital, Royal Oak eOakland University William Beaumont School of Medicine, Rochester, Michigan, USA Correspondence to Kimberly A. Drenser, MD, PhD, William Beaumont Hospital, Neuroscience Center, 3555W. 13 Mile Road, Suite LL-20, Royal Oak, MI 48073, USA. Tel: +1 650 380 1681; e-mail: email@example.com Current Opinion in Ophthalmology: May 2020 - Volume 31 - Issue 3 - p 207-214 doi: 10.1097/ICU.0000000000000656 Buy Metrics Abstract Purpose of review The aim of this article is to review and discuss the history, current state, and future implications of promising biomedical offerings in the field of retina. Recent findings The technologies discussed are some of the more recent promising biomedical developments within the field of retina. There is a US Food and Drug Administration-approved gene therapy product and artificial intelligence device for retina, with many other offerings in the pipeline. Summary Signaling pathway therapies, genetic therapies, mitochondrial therapies, and artificial intelligence have shaped retina care as we know it and are poised to further impact the future of retina care. Retina specialists have the privilege and responsibility of shaping this future for the visual health of current and future generations. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.